NASDAQ$ZNTL
Zentalis Pharmaceuticals Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Zentalis reported financial results and provided operational updates
Zentalis Pharmaceuticals reported a cash balance of $516.6 million as of September 30, 2023, projecting a cash runway into 2026. The company is focused on advancing azenosertib, with plans to submit the first NDA in a gynecologic malignancy in 2026. Updated data from the azenosertib monotherapy study showed a 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients.
- Azenosertib monotherapy program showed continued anti-tumor activity with intermittent dosing, with a 37% ORR and mPFS of 6.5 months in platinum resistant or refractory ovarian cancer and uterine serous carcinoma patients.
- Azenosertib development strategy is on track to submit its first New Drug Application (NDA) for azenosertib in a gynecologic malignancy in 2026.
- The company plans to evaluate azenosertib in platinum sensitive ovarian cancer (PSOC) in the first-line (1L) maintenance setting in the clinic.
- Mark Lackner, Ph.D., will succeed co-founder, Kevin Bunker, Ph.D., as Chief Scientific Officer at the end of the year.
Headline financials
Revenue & EPS history
Zentalis · Revenue · Quarterly
$600K
Forward guidance
Zentalis anticipates several milestones in the near future, including final results from multiple Phase 1 trials and topline data from Phase 1/2 and Phase 2 trials, as well as initiating a clinical trial of azenosertib in PSOC in the 1L maintenance setting in 2025.
Tailwinds
- Final results of Phase 1 azenosertib + chemotherapy (gemcitabine) trial in osteosarcoma (ZN-c3-003) in 1H 2024
- Final results of Phase 1b azenosertib monotherapy trial in solid tumors (ZN-c3-001) in 2H 2024
- Topline data from Phase 1/2 azenosertib + PARP inhibitor (niraparib) and azenosertib monotherapy trial in platinum resistant ovarian cancer in partnership with GSK (MAMMOTH, ZN-c3-006) in 2H 2024
- Initial data from Phase 1 azenosertib + BEACON regimen (encorafenib + cetuximab) trial in BRAF mutant metastatic colorectal cancer in partnership with Pfizer (ZN-c3-016) in 2H 2024
- Topline data from Phase 2 azenosertib monotherapy trial in platinum resistant high-grade serous ovarian cancer (DENALI, ZN-c3-005) in 1H 2025
Headwinds
- Potential delays in clinical trials due to unforeseen events.
- Risks associated with regulatory approval process.
- Dependence on the success of lead product candidates.
- Possibility of product candidates causing serious adverse side effects.
- Inability to maintain collaborations or failure of these collaborations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
-1.7%
Avg return
Earnings day
-2.2%
Avg return
5 days after
+2.4%
Avg return
30 days after
58%
14 / 24 earnings
Positive
+14.5%
Q1 2023
Best reaction
-43.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.9% | -1.7% | — | |
| Q4 2025 | +3.1% | -3.7% | +49.1% | |
| Q3 2025 | +6.2% | +0.8% | +9.8% | |
| Q1 2025 | -2.5% | +3.3% | +10.7% | |
| Q4 2024 | -12.6% | -15.0% | -23.5% | |
| Q3 2024 | -2.7% | -13.9% | -22.3% | |
| Q2 2024 | -8.8% | -12.5% | -10.6% | |
| Q1 2024 | +6.1% | +7.0% | -5.5% | |
| Q4 2023 | +10.0% | +8.5% | +11.9% | |
| Q3 2023 | -43.0% | -45.0% | -33.1% | |
| Q2 2023 | +5.3% | +11.2% | -0.5% | |
| Q1 2023 | +14.5% | +22.8% | +2.7% | |
| Q4 2022 | +1.2% | -2.1% | -9.1% | |
| Q3 2022 | -14.1% | -4.3% | -17.4% | |
| Q2 2022 | -0.1% | -7.3% | -8.1% | |
| Q1 2022 | -16.4% | -24.7% | +1.3% | |
| Q4 2021 | +7.6% | +5.7% | -3.2% | |
| Q3 2021 | +0.8% | -1.0% | -8.8% | |
| Q2 2021 | +4.9% | +7.1% | +39.0% | |
| Q1 2021 | -4.6% | -1.3% | -9.0% | |
| Q4 2020 | +1.4% | -0.7% | +45.7% | |
| Q3 2020 | -5.6% | -2.1% | +36.3% | |
| Q2 2020 | +1.0% | +7.2% | -10.6% | |
| Q1 2020 | +4.5% | +8.2% | +10.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro